Grow Your Business and Join MarketWorld Marketplace and Create Your Own Store front

Tuesday, June 18, 2024

HomeFinanceEU regulators approve BeiGene's tislelizumab for lung cancer (NASDAQ:BGNE)

EU regulators approve BeiGene’s tislelizumab for lung cancer (NASDAQ:BGNE)

EU Flags in front of European Commission European Union Flags

Mlenny

EU regulators have approved BeiGene’s (NASDAQ:BGNE) tislelizumab for the treatment of three types of non-small cell lung cancer, or NSCLC, including as a first and second-line treatment.

The product was approved as a first-line treatment for certain patients with squamous


Source link

Bookmark (0)
ClosePlease login
RELATED ARTICLES
- Advertisment -spot_img

Most Popular

Sponsored Business

- Advertisment -spot_img